TherapeuticsMD (TXMD)

P/S ratio as of July 2026 (TTM): 7.21

According to TherapeuticsMD's latest financial reports and stock price the company's current price-to-sales ratio (TTM) is 0.8968. At the end of 2026 the company had a P/S ratio of 7.25.

P/S ratio history for TherapeuticsMD from 2003 to 2026

PS ratio at the end of each year

Year	P/S ratio	Change
2026	7.25	14.71%
2025	6.32	-11.47%
2024	7.14	-60.94%
2023	18.3	-11.98%
2022	20.8	1095.03%
2021	1.74	-68.93%
2020	5.59	-57.7%
2019	13.2	-76.77%
2018	56.9	-26.96%
2017	77.9	32.96%
2016	58.6	-36.03%
2015	91.6	98.15%
2014	46.2	-46.29%
2013	86.1	6.24%
2012	81.0	140.77%
2011	33.7	33.35%
2010	25.2	-98.7%
2009	> 1000
2007	1.04	-5.55%
2006	1.10	23.22%
2005	0.8899	-1.69%
2004	0.9052	-36.48%
2003	1.43

P/S ratio for similar companies or competitors

Company	P/S ratio	P/S ratio differencediff.	Country
Pfizer PFE	2.21	-69.31%	🇺🇸 USA
AbbVie ABBV	7.26	0.61%	🇺🇸 USA
Agile Therapeutics AGRX	0.4834	-93.30%	🇺🇸 USA
Royalty Pharma RPRX	13.8	91.52%	🇬🇧 UK
Lannett Company LCI	0.0238	-99.67%	🇺🇸 USA

What is the market capitalization of a company?

The market capitalization sometimes referred as Marketcap, is the value of a publicly listed company.
In most cases it can be easily calculated by multiplying the share price with the amount of outstanding shares.

DISCLAIMER

CompaniesMarketCap is not associated in any way with CoinMarketCap.com
Stock prices are delayed, the delay can range from a few minutes to several hours.
Company logos are from the CompaniesLogo.com logo database and belong to their respective copyright holders. Companies Marketcap displays them for editorial purposes only.

Contact

For inquiries or if you want to report a problem write to hello@8marketcap.com

Links

- Privacy policy

- Terms and conditions

P/S ratio for TherapeuticsMD (TXMD)

P/S ratio as of July 2026 (TTM): 7.21